Conference Report

Gastrointestinal Cancers

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Society for Medical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Gastrointestinal Cancers

Faculty:

Jim Cassidy, MB ChB, MSc, MD, FRCP
Chris Twelves, MD

CME CREDIT INFORMATION

Release Date: 11/05/08

Expiration Date: 11/04/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recent data on EGFR-targeted agents in combination with chemotherapy for patients with nonresectable colorectal cancer liver metastases
Explain the effects of sorafenib in patients with hepatocellular carcinoma with and without hepatitis B
Summarize the use of bevacizumab in combination regimens for colorectal cancer, including patients older than 65 years of age
Discuss the use of the novel vascular targeting agent NGR-hTNF in patients with gastrointestinal malignancies

Topics covered include:

Chemotherapy Plus Cetuximab in Colorectal Cancer
Sorafenib in Patients With Hepatocellular Carcinoma and Hepatitis B Virus Infection
Capecitabine vs 5-FU in Esophagogastric Cancer: The REAL 2 and ML17032 Trials
The Use of Bevacizumab in the Treatment of Older Patients With Colorectal Cancer
Antiangiogenic Agents in Combination Therapy in CRC
NGR-hTNF: A Novel Vascular Targeting Agent

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.